Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors

<p>Glioblastoma patient characteristics (DFCI)</p>

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Joseph Toker (15399882) (author)
Άλλοι συγγραφείς:	J. Bryan Iorgulescu (15030477) (author), Alexander L. Ling (15399885) (author), Genaro R. Villa (15399888) (author), Josephina A.M.A. Gadet (15399891) (author), Laxmi Parida (15112564) (author), Gad Getz (14945542) (author), Catherine J. Wu (14944480) (author), David A. Reardon (15043854) (author), E. Antonio Chiocca (15399894) (author), Marco Mineo (15399897) (author)
Έκδοση:	2025
Θέματα:	Cancer Cancer Detection and Diagnosis Immuno-oncology Biomarkers CNS Cancers Gliomas, Glioblastomas Immunotherapy Checkpoint blockade Skin Cancers Melanoma
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
ανά: Joseph Toker (15399882)
Έκδοση: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
ανά: Joseph Toker (15399882)
Έκδοση: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
ανά: Joseph Toker (15399882)
Έκδοση: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
ανά: Joseph Toker (15399882)
Έκδοση: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
ανά: Joseph Toker (15399882)
Έκδοση: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
ανά: Joseph Toker (15399882)
Έκδοση: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
ανά: Isha Mondal (16721699)
Έκδοση: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
ανά: Francesca Orzan (15055579)
Έκδοση: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
ανά: Francesca Orzan (15055579)
Έκδοση: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
ανά: Francesca Orzan (15055579)
Έκδοση: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
ανά: Michael Kilian (16697663)
Έκδοση: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
ανά: Michael Kilian (16697663)
Έκδοση: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
ανά: Michael Kilian (16697663)
Έκδοση: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
ανά: Sied Kebir (15048732)
Έκδοση: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
ανά: Sied Kebir (15048732)
Έκδοση: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
ανά: Sied Kebir (15048732)
Έκδοση: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
ανά: Sied Kebir (15048732)
Έκδοση: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
ανά: Sied Kebir (15048732)
Έκδοση: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
ανά: Defne Bayik (14961098)
Έκδοση: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
ανά: Qingsheng Xu (17078830)
Έκδοση: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
ανά: Qingsheng Xu (17078830)
Έκδοση: (2025)

Graphical abstract from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
ανά: Reza Mirzaei (15306062)
Έκδοση: (2025)

Supplementary Table S1 from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
ανά: Reza Mirzaei (15306062)
Έκδοση: (2025)

Supplementary Table S2 from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
ανά: Reza Mirzaei (15306062)
Έκδοση: (2025)

Figures 1 from Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma
ανά: Bachchu Lal (17141949)
Έκδοση: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
ανά: William Kelly (15439117)
Έκδοση: (2025)

Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
ανά: William Kelly (15439117)
Έκδοση: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
ανά: Anne-Florence Blandin (15056366)
Έκδοση: (2025)

Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
ανά: Tobias Kessler (17079209)
Έκδοση: (2025)

Supplementary Figure S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
ανά: Tobias Kessler (17079209)
Έκδοση: (2025)

Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
ανά: Tobias Kessler (17079209)
Έκδοση: (2025)

Supplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
ανά: Tobias Kessler (17079209)
Έκδοση: (2025)

Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
ανά: Tobias Kessler (17079209)
Έκδοση: (2025)

Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
ανά: Tobias Kessler (17079209)
Έκδοση: (2025)

Cannot write session to /tmp/vufind_sessions/sess_4au56av3lppsn7d798ijm0ohbg